The US Food and Drug Administration approved Guardant Health, Inc.’s Guardant360 CDx comprehensive genomic profiling test for patients with any solid malignant tumor, the company announced on 7 August.
The FDA also approved it as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor...